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Abstract
Background: CCR5 coreceptor using HIV-1 subtype C (HIV-1C) has been reported to dominate the Ethiopian
epidemic. However, almost all data have been obtained from two large cities in the central and north-west regions
and recent data is lacking.
Methods: Plasma were obtained from 420 treatment-naïve patients recruited 2009–2011 to a large country-wide
Ethiopian cohort. The V3 region was sequenced and the co-receptor tropism was predicted by the clinical and
clonal models of the geno2pheno tool at different false positive rates (fpr) and for subtype. In an intention to treat
analysis the impact of baseline tropism on outcome of antiretroviral therapy was evaluated.
Results: V3 loop sequencing was successful in 352 (84%) patients. HIV-1C was found in 350 (99.4%) and HIV-1A in
two (0.6%) patients. When comparing the geno2pheno fpr10% clonal and clinical models, 24.4% predictions were
discordant. X4-virus was predicted in 17.0 and 19.0%, respectively, but the predictions were concordant in only 6%.
At fpr5%, concordant X4-virus predictions were obtained in 3.1%. The proportion of X4-tropic virus (clonal fpr10%)
increased from 5.6 to 17.3% (p < 0.001) when 387 Ethiopian V3 loop sequences dated from 1984 to 2003 were
compared with ours. In an intention to treat analysis, 67.9% reached treatment success at month 6 and only 50% at
month 12. Only age and not tropism predicted therapy outcome and no difference was found in CD4+ cell gain
between R5-tropic and X4-tropic infected patients. At viral failure, R5 to X4 switch was rare while X4 to R5 switch
occurred more frequently (month 6: p = 0.006; month 12: p = 0.078).
Conclusion: The HIV-1C epidemic is monophylogenetic in all regions of Ethiopia and R5-tropic virus dominates,
even in patients with advanced immunodeficiency, although the proportion of X4-tropic virus seems to have
increased over the last two decades. Geno2pheno clinical and clonal prediction models show a large discrepancy
at fpr10%, but not at fpr5%. Hence further studies are needed to assess the utility of genotypic tropism testing in
HIV-1C. In ITT analysis only age and not tropism influenced the outcome.
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Background
Human immunodeficiency virus type 1 subtype C
(HIV-1C) was isolated for the first time in 1986 from
an Ethiopian patient [1] and the first near-full length
HIV-1C sequence was published in 1996 [2]. By pheno-
typic analysis, HIV-1C isolates were found to almost
exclusively use the CCR5 co-receptor for cell entry,
even in patients with advanced immunodeficiency [3].
With time genotypic algorithms were developed, which
enabled prediction of co-receptor usage based on V3
sequences of the envelope [4]. This approach is claimed
to be applicable with a high degree of confidence also
for HIV-1C, although no Ethiopian HIV-1C strains
(HIV-1CET) were included in these evaluations, to our
knowledge [5–7].
For HIV-1 subtype B (HIV-1B), virus using the CCR5-
receptor (R5-tropic) are predominant in early stages of
infection, whereas virus using the CXCR4-receptor
(X4-tropic) generally emerge in the advanced stages,
although ultra-deep sequencing has identified that X4-
variants coexist as minority strains with R5-virus in
most patients [8]. Previously, X4-tropic strains have
been reported to be very rare in HIV-1C infection,
even in the later stage of disease [9–11]. Some recent
studies from South Africa and India also showed pre-
dominance of R5 strains in treatment naïve as well as
experienced HIV-1C infected patients [12], although a
South African study reported predominance of X4 strains
in treatment experienced children [13]. More recently, a
higher incidence of X4-tropic HIV-1C were described in
patients with advanced immunodeficiency from South
Africa, India and Botswana, respectively [14–17]. How-
ever, recent tropism data from patients with progressive
HIV-1CET infection is lacking.
In order to obtain information about the present situ-
ation in Ethiopia, we predicted the co-tropism in the
largest number of HIV-1CET infected patients analysed
so far. Also, since earlier reports have been derived only
from the central (Addis Ababa) [18–20] and north-west
(Gondar) regions [21, 22], patients from six geograph-
ical regions and from a mobile military unit were in-
cluded. The aim was to get updated knowledge of
whether the Ethiopian HIV-1 epidemic had become
more heterogeneous and whether any regional differences
exist. We also assessed the impact of baseline tropism on




The study was conducted on 420 randomly selected
ART naïve adults and adolescents (>16 years) enrolled
between 2009 and 2011 in the large (n = 874) country-
wide Ethiopian Advanced Clinical Monitoring (ACM) of
HIV cohort. After inclusion to the ACM, the patients
were given ART, according to the national guidelines.
The patients were from clinics affiliated to medical
universities in six regions (East–Harar; West–Jimma;
North-west–Gondar; North–Mekele; South–Hawassa;
Central–Addis Ababa) and a clinic for the Ethiopian
military, the Mobile Group. From the 874 patients,
baseline plasma samples were available for 695 who
we stratified by study site and randomly selected 60
from each study site. Randomization was done using
Microsoft Excel program (Fig. 1). The study period
was 12 months and plasma was sampled at months 6
and 12. The samples were temporarily stored at −20 °C
and transported thereafter to the central laboratory of
the Ethiopian Health and Nutrition research institute
(EHNRI) where they were stored at −80 °C. Viral load
(VL) was analysed by MT 2000 real time PCR (Abbott,
USA) and CD4+ T-cells were quantified by FACSCount
(Becton Dickenson), at EHNRI. Ethical approval was
obtained from the Ethiopian Ministry of Science and
Technology and the EHNRI institutional review board.
Written informed consent was obtained before inclusion.
Database derived sequences
V3 sequences of HIV-1CET strains with a sampling date
between 1984 and 2003 (n = 387) were downloaded from
the Los Alamos database (accessed on 23th January 2015),
after selecting the first sequence per patient.
Genotypic co-receptor tropism and subtyping
HIV-1 RNA was extracted from plasma by QIAamp
Viral RNA kit (Qiagen, Hilden, Germany) and cDNA
was synthesized using RevertAid H-minus reagents (Life
technologies, Paisley, UK), following the manufacturer’s
instructions. The env gene encoding the V3-V4 region
was amplified by nested PCR as described [23], with
modified forward primer ES7 (5′ TTRTTAAATGGTAGT
ATAGC-3′; HXB2 nt 7001–7020) adapted for HIV-1CET
[24]. The amplicons were purified by QIAquick kit
(Qiagen) followed by bidirectional sequencing in auto-
mated sequencer (ABI 3130xl Genetic Analyzer, Ap-
plied Biosystems). Sequences were aligned, edited, and
analysed by the BioEdit software v. 7.0.9. The V3 loop
sequence was derived by gene cutter program [25] and
was translated to all possible amino acid sequences as
some nucleotide sequences had double peaks. Predic-
tion of co-receptor usage was done by the clonal and
the clinical Geno2Pheno algorithms as described else-
where [4, 26], where the clinical model includes clinical
data, such as nadir CD4 count and viral load, to improve
prediction in treatment naïve patients. Geno2Pheno is op-
timized for HIV-1B but has been claimed to have 95% spe-
cificity in predicting X4-tropism in HIV-1C [7]. The false
positive rate (FPR) was set to 10 and 5%, respectively, for
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X4 tropism and binary coded. The use of 10% FPR in-
creases the risk of falsely predict an HIV-1 strain as R5-
tropic as compared to the 5% FPR, which is of clinical
relevance if the CCR5-receptor antagonist maraviroc is
planned to be used. A virus was considered X4-tropic or
R5-tropic, if all amino acid sequences were predicted as
such. A virus that contained both kinds of amino acid se-
quences was classified as R5/X4-tropic [15]. Subtyping
was done by the REGA subtyping tool v3.0 [27], the RIP
3.0 [24, 28], and the COMET HIV [29].
Statistical analysis
Baseline socio-demographic and clinical characteristics
(gender, age, year of HIV diagnosis, year of enrolment,
CD4+ T-cells, VL) were included. The outcome of treat-
ment was assessed with both on-treatment and intention-
to treat (ITT) analysis. In the ITT analysis, ART failure was
defined as either of detectable VL (>1000 copies/ml), death,
lost-to-follow-up (LTFU) and missing data. Descriptive
analyses included frequencies for categorical variables,
and mean and standard deviation or median and inter-
quartile range for continuous variables. Chi-square test
or Fisher’s Exact Test was used to test differences between
categorical variables. Independent t-test, Mann-Whitney,
Anova and Kruskal-Wallis test assessed differences of nu-
merical variables between two or more categories. General
linear (GLM) and logistic regression models with back-
ward selection were used for the multivariable analysis of
immunological and virological responses. Beta coefficients
and Odds Ratios (OR), 95% Confidence interval and
p-values were used to present the regression models
results. P-values < 0.05 were considered significant. Data
analysis was done by the STATA software 13 (Stata Corp.




A flow chart of the patients from baseline to month 12
is depicted in Fig. 1. Baseline V3 loop sequencing was
Fig. 1 Flow chart of randomly selected patients. *Additional seven patients not included in the randomly selected group failed therapy and were
included for the purpose of co-receptor switch analysis only. VL: viral load (copies/ml)
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successful in 352 of the 420 (84%) patients (Table 1). No
difference in success rate was found between the sites.
From baseline to month 6, 33 patients had died, 28 were
lost to follow-up (LTFU) and 15 had a missing VL. Of
the remaining 276 (78.4%) subjects, 37 patients had a
virological failure (>1000 copies/mL; mean VL log10:
5.06; range: 3.1–7.0 copies/ml). At month 12, a further
ten patients had died, 28 subjects were LTFU and 55 pa-
tients had a missing VL. Of the remaining 198 (56.3%),
22 patients had virological failure (mean VL log10: 4.9;
range: 3.4–6.8 log10 copies/ml). Thus, 176 out of 352
(50.0%) reached treatment success in an ITT–analysis.
Subtyping
By the REGA tool, HIV-1C was found in 338 patients,
HIV-1A1 in one patient, while no subtype was assigned
for 13 patients. By RIP and COMET, the HIV-1C and
HIV-1A1 classifications were confirmed. A further 12 se-
quences were classified as HIV-1C and one as HIV-1A1
by both methods. Thus, altogether HIV-1C was found in
350 (99.4%) of the 352 patients and A1 in two (0.6%)
patients.
Baseline tropism at fpr10% in relation to CD4+ T-cell
counts and viral load
At baseline, 352 V3-nucleotide sequences were derived
from 352 patients. These nucleotide sequences were
translated into 668 amino acid sequences, which were
used for tropism prediction [15] (Table 2). The patients
contributed thereby with between one up to 32 amino
acid sequences each. By the clinical model fpr10%, the
following tropisms were predicted: R5–285 (79.0%); X4–
60 (17.0%); mixed R5 and X4 (R5/X4) 7 (2.0%). At lower
fpr%, the proportions of X4-virus were: fpr <2%: 4%; fpr
2–5%: 4%; fpr 5–10%: 11%) (Fig. 2a). By the clonal
model, the figures were: R5–291 (82.7%); X4–50 (14.2%);
R5/X4–11 (3.1%). At lower fpr%, the proportions of X4-
virus were: fpr <2%: 2.5%; fpr 2–5%: 6.3%; fpr 5–10%:
8.5% (Fig. 2b).
Altogether, 266 (75.6%) of the 352 predictions were
concordant between the two models at fpr10% (Table 2).
X4-virus was present in 107 (30.4%) by any of the two
models, but only 21 (6.0%) of the viruses were pure X4
by both models. A significant association was found be-
tween tropism and CD4+ T-cells by the clinical (p < 0.001),
but not by the clonal model (Table 2). No association was
found between tropism and age, gender or VL.
At the fpr5%, a 97.5% concordance was found between
the two models. X4 virus was predicted by any model in
47 (13.3%) of the 352 patients. The association between
tropism and CD4+ T-cells was significant by both models
(p = 0.001; p = 0.023, respectively), while VL was associated
with tropism by the clinical model only (p = 0.001).
Co-receptor tropism in different geographical regions of
Ethiopia
At fpr10%, there was no difference in occurrence of R5-
virus across the geographical regions by the clinical (p =
0.1) (Table 3) or the clonal (p = 0.2, data not shown)
models. At fpr5%, a significant geographical difference was
observed by the clinical (p = 0.01), but not by the clonal
model. The highest proportion of R5 tropic virus was ob-
served in north-west Ethiopia (100%), while the lowest
was observed in Southern Ethiopia (80%) (p = 0.001).
Temporal trends in X4 tropic virus among Ethiopian HIV-1
isolates
A total of 387 historical V3 loop sequences from HIV-1CET
dated from 1984 to 2003 were downloaded from Los Ala-
mos database (1984–1993: n = 91; 1994–2003: n = 296),
while our study yielded 352 sequences from year 2009 to
2011. Tropism was predicted by the clonal model at fpr10%
only since most historical sequences lacked clinical data.
The proportion of X4/R5-X4 tropic virus increased from
5.6% (1984–1993), 7.1% (1994–2003), to 17.3% (2009–
2011) (p < 0.001). At 5% fpr cut off, the proportion of X4/
R5-X4 tropic virus increased from 1.1% (1984–1993), 3.7%
(1994–2003) to 8.8% 2009–2011) (p = 0.003).
Impact of baseline HIV-1 tropism on therapy response
At month 6, 291 of the 352 patients were still on ART
(Fig. 1) among whom 276 (78.4%) had VL data. At
























Gender maleb 41.8% 38.5% 82.0% 30.6% 31.4% 32.0% 30.0% 48.0%
Age in years
(mean ± SD)
34.6 ± 9.1 36.5 ± 10.8 35.2 ± 6.8 34.2 ± 8.4 32.0 ± 8.0 35.3 ± 7.8 34.4 ± 8.9 34.5 ± 11.5
































aA sequencing attempt was done in 420 patients; bsignificant difference between study sites (p < 0.001); VL: viral load; IQR, interquartile range
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bivariate analysis, no difference was seen in the propor-
tion with plasma HIV RNA <1000 copies/mL between
R5- and X4-patients on ART. In ITT analysis, by the
clinical fpr10% model, X4-patients failed ART more
often than R5-patients (30/67 vs 82/285; p = 0.013).
Similar results were obtained with fpr5% (data not
shown). However, multivariable analysis showed no as-
sociation between tropism and outcome. In contrast,
age was strongly associated with outcome at month 6
(p < 0.03) (Table 4), older patients with lower odds of
achieving treatment success (OR = 0.922, 0.859–0.989).
At month 12, 263 were still on ART among whom 198
(56.2%) had VL data. No difference in treatment out-
come was seen between patients, who had R5 or X4
virus at baseline, on ART or by ITT analysis (bivariate
and multivariable). Similar results were obtained with
fpr5% (data not shown). In contrast, age was strongly as-
sociated with treatment outcome at month 12 in the
multivariable analysis (p < 0.009), older patients with
lower odds of achieving viral suppression (OR 0.920;
0.865–0.979) (Table 4). It should be noted that there was
no significant differences between different age groups
with regard to degree of immunodeficiency when the
patients were classified into three age groups (years)
<30, 30–49 and >50. Thus, the median (IQR) baseline
CD4+ T-cell counts were 118 (58–200), 144 (94–186)
and 116 (62–181), respectively (p = 0.547).
At bivariate on-treatment analysis, the CD4+ T-cells was
lower in X4-patients compared to R5-patients (fpr10%) at
month 6 (median CD4 cell count (IQR): 200 (107–248) vs
244 (152–341) p = 0.017), but not at month 12. Same re-
sults were obtained for fpr5% (data not shown). However,
the gain in CD4+ T-cells between baseline and month 6
did not differ between patients with R5-virus or X4-virus
(fpr10%) in on treatment analysis (median, IQR: 97 cells/μl,
31–182 versus 108 cells/μl, 42–159), neither at month 12
(data not shown). Similar results were obtained when the
fpr5% level was used (data not shown). In multivariable
analysis, no association was found between any of the
baseline predictors, including tropism, and CD4+ T-cell
increase (Table 5).
Switch of co-receptor tropism in patients with virological
failure
At month 6, virological failure was detected in 37 random-
ized patients and in additional seven non-randomized pa-
tients who were included only for the study of co-receptor
switch. Forty-one of these patients had a plasma sample
available. In their baseline samples, V3 sequencing was
successful in 34 patients and R5 tropic virus was found in
29 (86.5%) of them (clonal model). Tropism switch oc-
curred in two of 29 (7%) R5-patients and in two of five
(40%) X4-patients (Fisher exact test, p = 0.006) at month 6.
Table 2 Baseline tropism predicted by the geno2pheno clinical and clonal models, respectively, at the fpr10% level
Clinical model FPR 10% Clonal model FPR 10% Concordance between clinical and clonal modelsa
R5 X4 R5/X4 p-value* R5 X4 R5/X4 p-value* R5-R5 R5-X4 X4-R5 X4-X4 p-value**















































*Mann-Whitney U-Test; **Kruskal Wallis Test; aR5-R5: both models predicted R5 virus; R5-X4: clinical model predicted R5 virus and clonal model predicted X4 virus;
X4-R5: clinical model predicted X4 virus and clonal model predicted R5 virus; X4-X4: both models predicted X4 virus. VL: viral load (copies/ml)
Fig. 2 Proportions of patients with R5- or X4-tropic viruses by the
geno2pheno clinical model (a) and by the geno2pheno clonal
model (b). Pie plots represent: i) R5-infected (fpr >10%) patients by
the fpr ranges: 10–20%, 20–60%, >60%; ii) X4-infected (fpr ≤10%)
patients. Exploded bars represent the stratification of X4-infected
patients according to the fpr ranges: < 2%, 2–5%, and 5–10%. FPR,
False positive rate; R5, CCR5; X4, CXCR4
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There was no difference in VL between those who switched
tropism or not at baseline or at month 6 (data not shown).
At month 12, 22 subjects failed virologically in whom
V3 sequencing was successful in 19 (clonal model; R5:
n = 15; X4 or R5/X4: n = 4). Of these subjects, nine had
also had a failure at month 6. Sixteen of the patients
showed a stable tropism while the three of the four X4
or R5/X4–patients switched to R5. Of the nine patients
failing both at month 6 and month 12, the tropism at
month 6 was preserved at month 12 (R5: 8; X4: 1).
There was no difference in viral load between patients
who switched tropism or not at baseline or at month
12 (data not shown).
Discussion
HIV-1C was first described in Ethiopia in 1986 [1] and
studies have since then consistently shown that the Ethi-
opian epidemic is predominantly (97–100%) comprised
of HIV-1C [18–22]. However, these studies have been
done with very few exceptions in the larger cities of
Addis Ababa (env) in the central region [18–20] or Gondar
(pol) in the north-west [21, 22] and there is very limited
knowledge from other parts of the country. By analysing
the V3-loop of the largest number of HIV-1 strains ever se-
quenced from Ethiopia, we now report that HIV-1CET
dominates almost exclusively all over the country. Thus,
the Ethiopian HIV-1C epidemic is still monophylogenetic
despite that the virus is estimated to have been introduced
around 1970.
The geno2pheno tool was developed for HIV-1B, but it
is used also for other subtypes, including HIV-1C [5–7].
However, in view of the unique characteristics of the HIV-
1CET genome [30, 31] an evaluation of the geno2pheno for
HIV-1CET is warranted. Both clonal and clinical models
have a good performance when compared to phenotypic
assays [4, 32]. At fpr10%, the models predicted each that
around 20% of the strains were X4-tropic. However, a
large discrepancy was found and only 6% were X4-tropic
with both methods. Instead, when using fpr5% the con-
cordance between the models was much higher, 97.5%,
and the two models predicted concordantly X4-virus in
only 3.1%. A high fpr% is valuable to decrease the risk of
using the CCR5-antagonist maraviroc in patients with X4-
virus, which is however not available in Ethiopia. In order
to study pathogenesis a lower fpr% can be considered and
we thus found that at fpr5% the Ethiopian epidemic is al-
most exclusively caused by CCR5-tropic HIV-1CET, also in
patients with very advanced immunodeficiency.
In addition to the geno2pheno tools, several genotypic
tropism methods are available. A more basic approach
uses the 11/25 rule, which asserts a virus as X4-tropic if
amino acids at either positions 11 and 25 of the V3 loop
are positively charged [33]. More sophisticated models
have been developed that outperform the 11/25 rule, e.g.
position specific scoring matrix (PSSM) [34] and Pheno-
Seq [35]. The most widely used geno2pheno and PSSM
tools are highly concordant (>85%) [36]. In our study the
geno2pheno tools were chosen as the European Guide-
lines recommend its use [6]. Moreover, since we had ac-
cess to both CD4+ T-cell counts and viral load, the
geno2pheno clinical tool, which has not been assessed
earlier in an African setting, provided an option to poten-
tially improve the predictions. It can be argued that there
was only a 76% concordance between the clonal and clin-
ical predictions and that a third method could have re-
vealed this discordance. However, although a confirmatory
Table 3 R5-tropism across geographical regions of Ethiopia, predicted by the geno2pheno clinical model (X4 and X4/R5 combined)
Clinical model Central





Gondar n = 49
West
Jimma n = 51
North
Mekele n = 50
East







fpr10% 45 86.5% 41 82.0% 39 79.6% 43 84.3% 40 80.0% 44 88.0% 33 66.0% 285 81.0% 0.108
fpr5% 49 94.2% 46 92.0% 49 100% 49 96.1% 44 88.0% 47 94.0% 40 80.0% 324 92.0% 0.010
*Chi square test
Table 4 Multivariable analysis of baseline predictors of
virological treatment response in an intention to treat analysisa
Follow-up Predictor OR (95% CI)b p-value
Month 6 Viral tropism 1.000 (0.455–2.195) 1.000
Age (years) 0.922 (0.859–0.989) 0.031
Viral load 1.681 (0.915–3.090) 0.081
CD4+ T-cell count 0.997 (0.991–1.000) 0.184
Month 12 Viral tropism 0.905 (0.248–3.302) 0.857
Age (years) 0.920 (0.865–0.979) 0.009
CD4 cell count 0.995 (0.989–1.001) 0.125
aIntention to treat analysis where treatment failure was defined as viral load
>1000 copies/ml, death, LTFU or missing values; bOR: Odds ratio (logistic
regression model). Only variables that appeared in the final model are shown
except viral tropism
Table 5 Multivariable analysis of baseline predictors of CD4+
T-cell increase (cells/ul)
Follow-up Predictor β coefficient (95% CI)a p-value
Month 6 Viral tropism 5.8 (−42.1–53.6) 0.779
VL log 16.6 (−1.1–34.2) 0.066
Month 12 Viral tropism 7.9 (−33.7–49.7) 0.657
VL log 11.8 (−6.9–39.5) 0.168
aCD4 cell recovery difference between groups (General Linear Model, GLM).
Only variables that appeared in the final model are shown except viral
tropism. VL: viral load (copies/ml)
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method could have improved the prediction to some ex-
tent, we believe that none of the available genotypic
methods is a preferred golden standard. Further compari-
son between different genotypic and phenotypic methods
for the assessment of HIV-1C tropism is therefore
warranted.
The CD4 cells were indeed very low (median; clinical
model: 58 cells/μl; clonal model: 91 cells/μl) for X4-
tropic patients, but also the R5-tropic patients had an
advanced immunodeficiency (clinical model: 132 cells/μl;
clonal model: 125/μl) when fpr10% was used. This is in
concordance with an earlier study from Ethiopia in
which patients with R5-tropic virus had a CD4 count of
78 cells/μl [37]. In contrast, no difference in viral load
was found between the R5 and the X4 tropic infected
patients. However, it shall be noted that the determin-
ation of co-receptor usage by a cut-off of fpr2% has been
reported to be better associated with low CD4 cells and
more advance disease, as compared to fpr10%, when the
clonal model is used [38].
Almost all reports from Ethiopia on co-receptor usage
have been done on patients from Addis Ababa or Gon-
dar. Our study clinics were distributed all over the coun-
try and the highest prevalence of X4 tropic virus was
found in southern Ethiopia (Hawassa), while the lowest
was found in north-west part (Gondar) (0% versus 20%,
fpr5% clinical model). There were no clinical indications
or reports that patients in Hawassa got access to health
care at a later stage of disease. Also CD4 cell levels and
viral load were found to be independent on the geo-
graphical origin of the patients. The reasons to this dif-
ference remain to be determined and also whether the
clinical outcome and the pattern of the epidemic differ
in various geographical regions of Ethiopia.
At fpr10%, the bivariate analysis showed a lower rate
of virologic response in X4 tropic than in R5 tropic pa-
tients at month 6 and month 12, respectively, as well as
less CD4 cell increase at month 6. Earlier studies are
contradictory and some authors report that X4-infected
patients display poorer immunological recovery than R5-
infected patients [39, 40] or similar response rates re-
gardless of viral tropism [41]. Also, HIV-1 tropism has
been reported as an independent predictor of virologic
response to first-line ART with no influence on CD4 cell
count recovery [42]. Differences in the methodology im-
pede a direct comparison between these studies. Thus, it
is known when using next generation sequencing almost
all patients harbour X4-viruses in minor quasispecies, to
varying degrees [43]. Also, the choice of fpr is an im-
portant factor, e.g. a fpr <2% has been found to be an in-
dependent factor for lower virological response and poor
CD4 cell increase in HIV-1B patients [44]. Our bivariate
results which showed lower virologic response in X4 in-
fected patients both at month 6 and 12 is in agreement
with these findings. However, the multivariable analysis
showed higher age at the initiation of ART as the only
strong independent factor associated with virologic out-
come, with no difference in immunologic outcome both
at month 6 and 12.
Bidirectional switch at treatment failure has been re-
ported but without any dominance in either direction
[45, 46]. However, these studies were done on HIV-1B
infected patients. In our study, a switch from X4 to R5
was more common although the number of analysed
samples were low. Why a viral switch during rebound
seems to occur more frequently with R5-virus and if this
is a phenomenon which occurs only in HIV-1C patients
remains to be established.
We compared our data with historical sequence data
from the Los Alamos database and found an increasing
proportion of X4 virus during the last decade with the
clonal fpr10% model. It is of course possible that a selec-
tion bias in the database contributed to this possible
change in tropism pattern but since for most historical
sequences no information about CD4+ T-cell level (or
viral load) was available it was not possible to further
analyse whether our patients differed clinically from
those earlier reported. However, it shall be noted a simi-
lar increase in the proportion of X4 viruses has been re-
ported from South Africa and India [14, 47].
Conclusions
The epidemic in Ethiopia is still monophylogenetic with
almost exclusively HIV-1CET strains in all geographical
regions. R5-tropic strains still dominate to a high degree,
but when comparing historical data, an increase of X4
viruses seems to have happened. Although the geno2-
pheno models are reported to have a high sensitivity in
HIV-1C, our results showed a significant discrepancy in
predicting X4 tropism by the clinical and clonal model
at fpr10%, calling for assessment of the utility of tropism
testing strategies in future studies. This is especially im-
portant in countries where the use of the co-receptor
antagonist maraviroc is more common, which is not the
case in Ethiopia. In contrast, a high concordance between
the clinical and clonal models was seen at fpr5% giving
further support to the view that R5 strains still dominate
in Ethiopia.
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